Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06139458 · ClinicalTrials.gov registry record · NA
Cryocompression to Reduce Chemotherapy-induced Peripheral Neuropathy in Gynecologic Cancer - COHORT 2
A NA study of Gynecologic Cancer and Chemotherapy-induced Peripheral Neuropathy, sponsored by Duke University.
- Recruiting
- Registry status
- NA
- Development phase
- 190
- Enrollment target
- 2
- Study locations
NCT06139458: Recruiting NA study of Gynecologic Cancer and Chemotherapy-induced Peripheral Neuropathy, sponsored by Duke University.
NCT06139458 is a NA study of Gynecologic Cancer and Chemotherapy-induced Peripheral Neuropathy that is actively recruiting participants, run by Duke University. The registered enrollment target is 190 participants, below the 761-participant average among 55 other Gynecologic Cancer trials with a reported enrollment target (75% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06139458, a NA study of Gynecologic Cancer and Chemotherapy-induced Peripheral Neuropathy, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- NA
- Development phase
- 190 participants
- Enrollment target
- 2
- Study locations
Study Summary
The investigators aim to determine the effect of cryotherapy wraps plus compression therapy (henceforth referred to as cryocompression) versus cryotherapy wraps alone on the incidence and degree of chemotherapy-induced peripheral neuropathy in patients with gynecologic cancer using a noninferiority design. The investigators also aim to determine the effect of cryocompression versus cryotherapy on patient tolerability and patient and staff satisfaction.
Primary Outcome
The FACT-NTX is a patient self-reported 11-item questionnaire used for evaluating symptoms and concerns specifically associated with chemotherapy induced neuropathy. The total score ranges from 0-44, and a lower FACT-NTX score corresponds to worsening neuropathy. For both the FACT-NTX and the sensory subscale of the FACT-NTX, a significant decrease in the score is defined as a decrease exceeding 10% from baseline.
Conditions Studied
Interventions
- BEHAVIORAL Cryotherapy
- BEHAVIORAL Compression
Study Locations (2)
North Carolina
- Duke University Medical Center - Durham
Virginia
- Carilion Clinic - Roanoke
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2024-01-18 |
| Est. Completion | 2027-05-31 |
| Phase | NA |
What NCT06139458 shows while recruiting
NCT06139458 is an interventional study that assigns participants to a tested intervention. The registered 190 participants enrollment target is mid-sized for trials with a published cap, below the 761-participant average among 55 other Gynecologic Cancer trials with a reported enrollment target (75% lower).
The record links to 2 conditions, with Gynecologic Cancer appearing as the primary indexed condition, and to 2 interventions - of which Cryotherapy is the first listed.
NCT06139458 reports a single indexed study location in North Carolina, Virginia.
Frequently Asked Questions
What is clinical trial NCT06139458 about?
NCT06139458 is a clinical study titled "Cryocompression to Reduce Chemotherapy-induced Peripheral Neuropathy in Gynecologic Cancer - COHORT 2". The investigators aim to determine the effect of cryotherapy wraps plus compression therapy (henceforth referred to as cryocompression) versus cryotherapy wraps alone on the incidence and degree of chemotherapy-induced peripheral neuropathy in patients with gynecologic cancer using a noninferiority ...
What is the current status of trial NCT06139458?
This trial is currently recruiting. It is a NA study. The enrollment target is 190 participants. The study started on 2024-01-18. Estimated completion is 2027-05-31.
What conditions does trial NCT06139458 study?
This clinical trial studies the following conditions: Gynecologic Cancer, Chemotherapy-induced Peripheral Neuropathy.
What interventions are being tested in trial NCT06139458?
The interventions under investigation include: Cryotherapy (BEHAVIORAL), Compression (BEHAVIORAL).
Who is sponsoring clinical trial NCT06139458?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06139458 being conducted?
This trial has 2 study locations across North Carolina, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gynecologic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06139458's enrollment target sits among peer trials
190 12th of 55 higher than 44 of 55 other Gynecologic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gynecologic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors
RECRUITING · NA
-
Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment
RECRUITING · NA
-
BOLSTER: Learning New Skills to Thrive
RECRUITING · NA
-
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
RECRUITING · NA
-
Activity Coaching During Pelvic Radiation Therapy
RECRUITING · NA
-
Transcranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy in Breast and Gynecologic Cancer Survivors
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03257033 · 190 participants · Phase 3
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
- NCT03642028 · 190 participants · Phase 4
Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress
- NCT04015609 · 190 participants · NA
Psychotherapy Intervention for Latinos With Advanced Cancer
- NCT04284397 · 190 participants · Early Phase 1
Identification of Critical Thermal Environments for Aged Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI